Viral Destruction: Sponsored Q&A by Microthermics
A range of industries?biotechnology, food and pharmaceuticals?must keep viral contamination out of their products. To do this effectively, a company needs a reliable, continuous process, and one that can be scaled to the company?s specific needs. To explore these topics, BioPharm International talked with John Miles, PhD, president and founder of MicroThermics Inc. This company specializes in small-scale solutions in high-temperature short-time (HTST) and ultra-high temperature (UHT) processes.
A range of industries—biotechnology, food and pharmaceuticals—must keep viral contamination out of their products. To do this effectively, a company needs a reliable, continuous process, and one that can be scaled to the company’s specific needs. To explore these topics, BioPharm International talked with John Miles, PhD, president and founder of MicroThermics Inc. This company specializes in small-scale solutions in high-temperature short-time (HTST) and ultra-high temperature (UHT) processes.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
